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Abstract
Disease causing aberrations in both tuberous sclerosis predisposing genes, TSC1 and TSC2, comprise nearly every type of
alteration with a predominance of small truncating mutations distributed over both genes. We performed an RNA based
screening of the entire coding regions of both TSC genes applying the protein truncation test (PTT) and identified a high
proportion of unusual splicing abnormalities affecting the TSC2 gene. Two cases exhibited different splice acceptor
mutations in intron 9 (IVS9315GCA and IVS933CCG) both accompanied by exon 10 skipping and simultaneous usage
of a cryptic splice acceptor in exon 10. Another splice acceptor mutation (IVS38318ACG) destroyed the putative
polypyrimidine structure in intron 38 and resulted in simultaneous intron retention and usage of a downstream cryptic splice
acceptor in exon 39. Another patient bore a CCT transition in intron 8 (IVS8+281CCT) activating a splice donor site and
resulting in the inclusion of a newly recognised exon in the mRNA followed by a premature stop. These splice variants
deduced from experimental results are additionally supported by RNA secondary structure analysis based on free energy
minimisation. Three of the reported splicing anomalies are due to sequence changes remote from exon/intron boundaries,
described for the first time in TSC. These findings highlight the significance of investigating intronic changes and their
consequences on the mRNA level as disease causing mutations in TSC. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Tuberous sclerosis complex (TSC) is an autosomal
dominant disorder characterised by the development
of hamartomas which a¡ect the brain, heart, skin,
kidney, lung and eyes. Two disease causing genes,
TSC1 on chromosome 9q34 (MIM 191100) [1] and
TSC2 on chromosome 16p13 (MIM 191092) [2],
were identi¢ed by positional cloning. LOH of
TSC1 and TSC2 loci in TSC-associated hamartomas
as well as in sporadic tumours of non-TSC patients
support the tumour suppressor function of both
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genes [3^5]. The genomic regions of both TSC genes
extend over about 40 kb. The 23 exons of the TSC1
gene are transcribed into a 8.6 kb transcript of which
21 exons encode for the protein hamartin. The TSC2
gene consists of 41 exons encoding a mRNA of 5.5
kb translated into tuberin. The C-terminal region of
tuberin has homology to rap1GAP and has been
shown to interact with rabaptin5. This region exhib-
its GTPase activating properties for Rap1 and Rab5
[6,7], two Ras-related proteins with functions in mi-
togenesis, endocytosis, and neuronal di¡erentiation.
Physical interaction of tuberin and hamartin medi-
ated by their coiled-coil domains has been demon-
strated in vivo by use of the yeast two-hybrid system
and by co-immunoprecipitation [8,9]. These ¢ndings
and the intracellular co-localisation of both proteins
[10] support a common cellular function of TSC1
and TSC2.
Mutation analyses have reported nearly 300 di¡er-
ent TSC1 and TSC2 mutations (The Human Gene
Mutation Database, Cardi¡; TSC Variation Data-
base). The major proportions in both genes are
subtle mutations composed of nonsense mutations,
small deletions and insertions, splice site changes,
and, for TSC2, additionally missense mutations. All
these mutations are distributed over the entire re-
gions of both genes.
Among the large number of TSC mutations iden-
ti¢ed as disease causing, only a few a¡ect splicing
regulatory sites. RNA splicing mutations are known
to occur in a number of disorders, and represent
approximately 10% of the total number of defects
identi¢ed world wide [11]. Most of them a¡ect the
5P donor and 3P acceptor consensus sites. The fre-
quency and nature of TSC splice site mutations re-
ported so far are in agreement with these overall
¢ndings: in TSC1 they represent 8% and in TSC2
they comprise 12% of the total number of identi¢ed
mutations. Most changes were merely assumed to
in£uence the mature transcripts, especially when
they a¡ect highly conserved sequences at exon/intron
junctions, while few are con¢rmed on the transcript
or the protein level.
We applied the protein truncation test (PTT) as an
RNA based screening procedure for the detection of
inactivating mutations in both TSC genes and iden-
ti¢ed truncating mutations extending the known di-
versity of small mutations in TSC2. By the combina-
tion of RT-PCR, PTT and cloning of abnormal
transcripts we identi¢ed two complex splicing aber-
rations in the TSC2 gene leading to simultaneous
expression of di¡erent abnormal transcripts: the
¢rst example was an identical splicing defect identi-
¢ed in individual patients accompanied by two di¡-
erent splice acceptor mutations in intron 9
(IVS9315GCA and IVS933CCG); the second
changed the polypyrimidine structure in intron 38
(IVS38318ACG). One further intronic mutation
(IVS8+281CCT) created a splice donor site and
led to the incorporation of an additional exon in
the RNA. It is well known that splice site, branch
point, enhancer and silencer sequences are accompa-
nied by characteristic secondary structures. Therefore
we have tried to verify the interpretations of muta-
tion induced alterations by RNA secondary structure
analysis. This report describes for the ¢rst time dif-
ferent TSC2 splicing defects due to intronic muta-
tions remote from exon/intron boundaries and their
consequences on the transcript level.
2. Materials and methods
2.1. Patients
Our patients belong to a group of 18 TSC2 cases
in whom the causal mutation had been identi¢ed
[12]. All ful¢lled the diagnostic criteria of Gomez
[13,14].
Systematic mutation screening included Southern
blot analysis of the TSC2 gene using the complete
TSC2 cDNA as a hybridisation probe followed by
the protein truncation test applied to the complete
coding regions of both TSC genes. Genomic DNA
was prepared from blood leukocytes by standard
procedures. For RNA based analyses leukocytes pu-
ri¢ed from peripheral blood were subjected to Ep-
stein^Barr virus immortalisation of B lymphocytes.
2.2. Reverse transcriptase PCR and ampli¢cation of
genomic DNA
Total cytoplasmic RNA from immortalised B lym-
phocytes was extracted using Tri reagent (Sigma)
based on a standard procedure. Reverse transcription
reactions were catalysed by superscript II reverse
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transcriptase (Life Technologies) and were carried
out in parallel with oligo(dT) (d(pT)15) and random
hexanucleotides (Boehringer) added as primers. The
entire coding regions of both TSC genes were ampli-
¢ed in four partially overlapping fragments synthe-
sised with TSC1 speci¢c primer pairs and six parti-
ally overlapping fragments generated with TSC2
speci¢c primer pairs as described earlier [12]. For
the con¢rmation of splicing abnormalities individual
cDNA and genomic DNA fragments were ampli¢ed
with appropriate exonic or intronic primers (Table
1).
Standard touchdown PCR reactions of 35 cycles
were catalysed by recombinant Taq polymerase (Life
Technologies) with 1 Wl cDNA or 100 ng genomic
DNA as a template.
2.3. In vitro transcription/translation
RT-PCR products (100^200 ng) were directly sub-
jected to transcription and translation in a TNT
coupled reticulocyte lysate system (Promega) as
described earlier [12]. Polypeptides were labelled
with 35S-methionine and separated through SDS^
PAGE in 10% and 12% denaturing gels at 25 mA
and 10‡C. Signals were ampli¢ed by incubation with
1 M sodium salicylate before vacuum drying of
the gels and autoradiography at 370‡C for 1^3
days.
2.4. Sequence analysis
RT-PCR products resulting in aberrant migrating
polypeptides were cloned into a T-vector (pCR2.1;
Invitrogen). Wild-type and mutated alleles of a pa-
tient’s transcripts were separated by performing a
second PTT reaction of RT-PCR clones [15]. Se-
quence analysis of selected RT-PCR clones were per-
formed with Sequitherm EXCEL II kit (EpiCentre)
in both directions using IRD-labelled primers and
analysed by an automated sequencer (LICOR). The
existence of aberrantly spliced transcripts was veri-
¢ed by direct ampli¢cation and sequencing of appro-
priate RT-PCR products. The underlying mutation
was con¢rmed in genomic DNA of a blood sample
from the corresponding patient.
2.5. Con¢rmation of mutations and SNP haplotyping
by restriction enzyme analysis
The possibility of intronic mutations located re-
mote from exon/intron boundaries to represent poly-
morphisms was lessened by excluding them in PCR
products derived from genomic DNA of healthy
family members and 50 controls by restriction en-
zyme analysis. IVS8+281CCT creates an additional
HphI site in the tested fragment spanning intron 8 to
exon 9. IVS9315GCA destroys a NciI site in the
tested fragment spanning intron 9 to intron 10. IVS-
38318ACG creates a CfrI site in the tested frag-
ment spanning exons 38 to 41. Primers used for am-
pli¢cation are listed in Table 1.
Generation of aberrant transcripts from the allele
bearing an intronic mutation was tested by segrega-
tion of published polymorphisms in the TSC2 coding
region (TSC Variation Database). Transcripts span-
ning exons 1^11 and those spanning exons 9^20 were
analysed for 18 and 22 polymorphisms, respectively,
by restriction analysis for those changing enzyme
recognition sites or sequencing. Transcripts spanning
exons 38^41 were tested for an EcoRV polymor-
phism in exon 40. For an identi¢ed polymorphism
in the RT-PCR fragments heterozygosity was con-
¢rmed by sequencing PCR fragments ampli¢ed
from genomic DNA including both the polymorphic
site and the site of the intronic mutation.
Table 1
Primer pairs used for con¢rmation of aberrant transcripts and sequencing of genomic DNA
PCR fragment Forward Reverse
Exons 8^11 5P-TGATGCGGAACCTCCTTGGCAC-3P 5P-CCACCAGTTCAAAGTATCTCTCCTG-3P
Exon 8^intron 8 5P-TGATGCGGAACCTCCTTGGCAC-3P 5P-CAGGCTAAGTAGTTGGGGAGCACC-3P
Intron 8^exon 9 5P-GTTCAACAGAATATCCACACCCAGCTC-3P 5P-CAACACAGATGTCGGCGAGTTCC-3P
Intron 9^intron 10 5P-GTTTCTGCGGCCCCTGATAAACG-3P 5P-CCAAGGTACCATCTTCTGAGTGG-3P
Exons 38^41 5P-CAACTTTGTCCACGTGATCGTCAC-3P 5P-TCACTGACAGGCAATACCGTCCAA-3P
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2.6. Secondary structure analysis of TSC2 pre-mRNA
To investigate the secondary structure of RNA
sequences by minimising the free energy we used
RNA-fold version 1.00.42 based on an algorithm de-
veloped by Zuker and Stiegler [16]. In order to get
relevant results it was necessary to take into account
biological and physico-chemical conditions given by
the transcription, folding and splicing process taking
place more or less simultaneously. Especially we have
chosen sequence parts of di¡erent position and
length within the region of interest which were built
up by small steps to produce the structures shown in
Figs. 1C, 2C, 3C.
3. Results
RNA based screening of the entire coding regions
of both TSC genes by PTT revealed all known types
of small truncating mutations in TSC1 and TSC2
[12]. This paper describes in detail four di¡erent
new splice mutations identi¢ed in ¢ve patients. These
include the generation of an additional exon in one
case, three patients with identical splicing defects
caused by di¡erent intronic mutations, and one pa-
tient with retention of the entire intron.
All splicing phenomena were initially identi¢ed
through PTT of di¡erent TSC2 fragments, were elu-
cidated through cloning, in vitro transcription/trans-
lation and sequencing of RT-PCR fragments, and
were ¢nally con¢rmed by an intronic change on the
DNA level. Complex splicing aberrations are illus-
trated in detail in Figs. 1^3.
In patient T31 the ¢rst indication for a truncating
mutation was visible after PTT of TSC2 exons 1^11
(Fig. 1A). Cloning and sequencing of RT-PCR prod-
ucts representing the mutated allele led to the iden-
ti¢cation of a 89 bp insertion between exon 8 and
exon 9 (Fig. 1D). The increase in size was hardly
Fig. 1. Aberrant splicing of an additional TSC2 exon, designated 8a, into the transcripts of patient T31 due to a CCT transition at
position +281 in intron 8 thereby creating a new splice donor site. A: PTT of TSC2 cDNA spanning exons 1^11 revealed an addi-
tional shortened in vitro translated protein band in patient T31. Analysis of cloned RT-PCR fragments in another PTT reaction re-
vealed the same shortened protein band in those clones representing the mutated allele. B: RT-PCR analysis of TSC2 exons 8^11 in
patient T31. Sequencing of the RT-PCR clones leading to the shortened polypeptide revealed an insertion of 89 bp between exon 8
and exon 9 which can also be proven by direct ampli¢cation of the cDNA spanning exons 8^11. C: RNA secondary structuring. The
upper and the lower parts contain the wild-type and the mutated sequence, respectively. Mutation sites are set o¡. Cryptic splice sites
used in the aberrant transcript are marked with arrows. Unstructured regions are represented by lines. Positions are numbered accord-
ing to the ¢rst nucleotide of intron 8 starting with +1. D: Schematic drawing of the aberrant splicing event inserting 89 bp of intron
8 between exon 8 and exon 9 in mature transcripts of patient T31. The sequence of the cryptic exon 8a is boxed. Translation of exon
8a leads to 38 novel amino acids and a stop in exon 9 which is underlined. Intron 8 contains a splice acceptor consensus sequence up-
stream of ‘exon 8a’ which is underlined.
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detectable in the full length RT-PCR fragment ex-
tending over 1239 bp used for PTT but could easily
be identi¢ed by ampli¢cation of a 450 bp fragment
spanning exons 8^11 (Fig. 1B). Additional PCR re-
actions with an insertion speci¢c primer and the sec-
ond primer complementary to adjacent exon 8 or
exon 9 sequences respectively (Table 1), performed
on genomic DNA, identi¢ed the 89 bp insert as an
intron 8 speci¢c sequence located 190 bp downstream
to the 3P end of exon 8 (Fig. 1D). Translation of this
89 bp insertion leads to the incorporation of 38 novel
amino acids C-terminal of exon 8 followed by a pre-
mature stop at codon 292 in exon 9 as visible in the
PTT (Fig. 1A). The genomic alteration responsible
for this aberrant splicing event is likely to be a
CCT transition identi¢ed at position +281 in intron
8. The mutation induced changes (sequence and
structure) activate a splice donor site of an already
existing complete functional entity of an exon in the
intron consisting of branch point, acceptor and do-
BBADIS 61986 25-10-00
K. Mayer et al. / Biochimica et Biophysica Acta 1502 (2000) 495^507500
nator splice site as revealed by secondary structure
analysis (Fig. 1C). As a consequence, a cryptic exon,
designated 8a, is inserted into mature transcripts.
Three other patients (T10 and T58, and T64 not
shown) showed identical truncated proteins after
transcription/translation of TSC2 exons 9^20 due
to an in frame deletion of exon 10 in the cDNA
(Fig. 2A). Cloning and sequencing of individual
RT-PCR products revealed transcripts lacking the
entire exon 10 and additionally transcripts with a
deletion of the ¢rst 56 bp of exon 10. Due to a
stop after six novel amino acids in exon 10 in the
latter the arising proteins could not be detected after
translation of exons 9^20 (Fig. 2A) and could not be
distinguished in size from proteins lacking complete
exon 10 in a PTT of exons 1^11 (not shown). Careful
analysis of RT-PCR products spanning exons 9^20
could also proof the existence of two additional aber-
rantly spliced transcripts after direct ampli¢cation
(Fig. 2B) of the patients’ cDNA. Sequencing of
intron 9 identi¢ed two di¡erent splice acceptor
mutations: IVS9315GCA in patient T10 and
IVS933CCG in patient T58 which can explain the
two simultaneous splicing consequences in both pa-
tients (Fig. 2D). The secondary structure analysis
positions the mutation sites IVS9315GCA and
IVS933CCG into an often observed structure mo-
tive between branch point and splice acceptor site
[17] and into the splice acceptor site, respectively.
The base change 315GCA alters the ¢rst structure
and 33CCG destroys the second one completely.
The mutation IVS9315GCA was identi¢ed in an
additional patient (T64) [12] who shows exactly the
same splicing pattern (data not shown) as patient
T10. Genomic deletions were excluded by ampli¢ca-
tion of overlapping PCR fragments spanning exons
9^11 in all three patients.
Patient 3493 represented a further example of a
complex aberrant splicing event with simultaneous
intron retention and usage of an internal splice ac-
ceptor due to a splice acceptor mutation (Fig. 3). The
¢rst striking observation in this patient was a faint
but reproducible truncated protein band in a PTT of
TSC2 exons 33^41 (Fig. 3A). Cloning and sequenc-
Fig. 2. Skipping of TSC2 exon 10 and usage of a cryptic splice acceptor in exon 10 accompanied by di¡erent splice acceptor muta-
tions in intron 9. A: PTT of TSC2 exons 9^20 shows the same truncated polypeptides due to di¡erent splicing events. B: RT-PCR of
the entire fragment spanning exons 9^20 used for PTT con¢rmed the existence of two additional aberrantly spliced transcripts in pa-
tients T10 and T58 in di¡erent ratios: those lacking the entire exon 10 and those lacking the ¢rst 56 bp of exon 10. C: RNA second-
ary structuring. The upper and the lower parts contain the wild-type and the mutated sequence, respectively. Mutation sites are set
o¡. The natural splice site in the wild-type transcript and the cryptic splice site used in the aberrant transcripts are marked with ar-
rows. Unstructured regions are represented by lines. Positions are numbered according to the ¢rst nucleotide of exon 10 starting with
+1. D: Schematic drawing of the aberrant splicing events identi¢ed in patients T10, T58. Both independent splice acceptor mutations
IVS9315GCA and IVS933CCG are accompanied by (a) mature transcripts with in frame skipping of exon 10 deleting 48 amino
acids and (b) transcripts which lack the ¢rst 56 bp of exon 10 due to usage of an internal splice acceptor in exon 10. The latter cate-
gory ¢nally ends in a premature stop after six novel amino acids. Splice acceptor consensus sequences in intron 9 and in exon 10 are
indicated, positions with sequence changes are underlined.
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ing of RT-PCR fragments classi¢ed by indistinguish-
able shortened size of the transcribed/translated pro-
tein allowed the identi¢cation of two di¡erent types
of mutated transcripts. The ¢rst class harboured the
entire 101 bp of intron 38 and the second category
was characterised by a deletion of the ¢rst 74 bp of
exon 39. Both aberrant splicing events, intron 38
retention as well as usage of an internal splice accep-
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tor in exon 39, lead to the incorporation of 13 and 14
novel amino acids, respectively, before a translation-
al stop occurs (Fig. 3D). This explains the indistin-
guishable size of the resulting proteins (Fig. 3A). The
existence of the two additional abnormal transcript
types was con¢rmed by direct ampli¢cation of RT-
PCR fragments spanning exons 38^41 (Fig. 3B). Se-
quence analysis of intron 38 in patient 3493 identi¢ed
an ACG transition at position 318. The G substi-
tution is also present in the transcripts containing the
retained intron 38 (not shown). Secondary structures
illustrate the experimental facts (Fig. 3C). Compara-
ble with IVS9315GCA the mutation IVS-
38318ACG occurs in a structure motive between
branch point and splice acceptor site. In contrast to
the case described before the structure change is fol-
lowed by retention of intron 38 instead of splicing
exon 39 as discussed in Chebli et al. [17]. The simul-
taneous splicing of 74 bp of exon 39 using the cryptic
branch point and splice acceptor site existing in exon
39 follows the same scheme as illustrated for the
mutations in intron 9 (Fig. 2C).
4. Discussion
We applied the PTT as an RNA based mutation
screening technique for the entire coding regions of
both TSC genes and identi¢ed splicing abnormalities
to represent 63% (12/19) of all small truncating mu-
tations detected in the TSC2 gene compared to 33%
(3/9) for the TSC1 gene [12]. Six of the 12 TSC2
splicing mutations identi¢ed by us represent di¡erent
mutations not previously described. Together with
other mutation screening reports which identi¢ed a
total of 14 di¡erent splice site aberrations a¡ecting
the TSC2 gene this corresponds to 12% of all pub-
lished small mutations in TSC2 (HGMD Cardi¡).
With two exceptions which harbour genomic dele-
tions [18,19] these were caused by mutations in direct
Fig. 3. Retention of TSC2 intron 39 and usage of an internal splice acceptor in exon 39 due to a splice acceptor mutation between
the branch point and the splice acceptor site of intron 38. A: PTT of TSC2 exons 33^41 identi¢ed a shortened protein band in pa-
tient 3493 which was con¢rmed by in vitro translation of the cloned RT-PCR fragment from two di¡erent types of clones: one har-
bouring an insertion between exon 38 and exon 39 and the other containing a deletion in exon 39. B: RT-PCR analysis of TSC2
exons 38^41 in patient 3493. The aberrant transcripts for which sequence analysis identi¢ed the retention of the entire intron 39 in
one case and the deletion of the ¢rst 74 bp of exon 39 in the other case has also been proven by direct ampli¢cation of the cDNA
fragment spanning exons 38^41 (the second visible band with increased size is due to heteroduplex formation between wild-type and
intron containing transcripts). C: RNA secondary structuring. The upper and the lower parts contain the wild-type and the mutated
sequence, respectively. Mutation sites are set o¡. The natural splice site in the wild-type transcript and the cryptic splice site used in
the aberrant transcripts are marked with arrows. Unstructured regions are represented by lines. Positions are numbered according to
the ¢rst nucleotide of exon 39 starting with +1. D: Schematic drawing of the aberrant splicing event simultaneously leading to (a)
transcripts with retention of intron 38 and (b) transcripts lacking the ¢rst 74 bp of exon 39 due to usage of an internal splice acceptor
in exon 39. Translation of both transcript types results in a premature stop after 13 novel amino acids in intron 39 and after 14 novel
amino acids in exon 40, respectively. Splice consensus sequences in intron 38 and in the cryptic acceptor site in exon 39 are indicated.
The sequence change is underlined.
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neighbourhood of the exon/intron boundaries. We
describe the detection and analysis of four new
splicing defects in TSC2 including three complex
aberrations due to intronic changes remote from
highly conserved exon/intron boundaries. The e¡ects
of all splicing defects were studied on the transcript
level. The most frequently used exon scanning meth-
ods restricted to DNA will also detect splice site
mutations if primer binding sites are located far
enough from exon/intron boundaries. But for in-
tronic nucleotide changes the disease causing e¡ects
have to be con¢rmed, especially if they are located
outside from the highly conserved splice consensus
sequences.
Splice site mutations have been estimated to ac-
count for 15% of all disease causing small mutations
[20] and can be calculated to represent about 10%
among all gene mutations listed in the Human
Gene Mutation Database [11]. However, their fre-
quencies may be higher in certain diseases, and this
strongly depends on mutation screening techniques
applied. Mutation reports in TSC have shown that
RNA based techniques are appropriate for the initial
detection [18,21,22] as well as for the ¢nal proof
[19,23] of splicing aberrations. Initial data from other
disease causing genes support the necessity to search
for complex splice site mutations with sensitive tech-
niques, as reported for muscular dystrophy type
Duchenne (DMD) and Becker (BMD) [24^26], neu-
ro¢bromatosis type 1 (NF1) [27] and type 2 (NF2)
[28], multiple endocrine neoplasia type 1 (MEN1)
[29], metabolic diseases like propionic acidemia
[30,31], and ataxia-teleangiectasia (ATM) [32].
Most frequent splicing defects are caused by se-
quence changes in the invariant splice donor and ac-
ceptor sites at positions +1, +2, and 31, 32, respec-
tively. A common e¡ect of those splice site mutations
is exon skipping [33]. Alternatively, cryptic splice
sites can be activated in the adjacent exon or intron
sequences, or a¡ected introns can be retained if they
are small enough [34]. Simultaneous realisation of
more than one possible splicing variant due to a
single mutation was reported only in a few cases of
human diseases like Tyrosinemia type 1 [35] and re-
cessive dystrophic epidermolysis bullosa [36]. The
combination of a mutation located remote from a
consensus splice site resulting in several aberrant
splicing consequences is exceptional with examples
described in Sandho¡ disease [37] and ataxia-telean-
giectasia [32].
Deletion of entire exons is considered to have a
dramatic e¡ect on protein function if an essential
domain is a¡ected, even if the reading frame is main-
tained. This appears to be accurate in cases T10,
T64, and T58 in whom exon 10 of the TSC2 message
is deleted because the interaction domain for hamar-
tin [8] is removed. Additionally, a proportion of the
aberrant transcripts in these patients miss the ¢rst 56
bp of exon 10 followed by a translational stop. Both
variants are suspected to be associated with the splice
acceptor mutations IVS933CCG and IVS9315G-
CA. In frame skipping of TSC2 exon 10 has not
only been observed in four of our patients [12] but
was also reported by Beauchamp et al. [19] where it
is likely to be the consequence of another splice ac-
ceptor mutation in intron 9 (IVS931GCA). Besides,
van Bakel et al. [18] identi¢ed in frame skipping of
exons 10 and 11 due to a 23 bp genomic deletion in
exon 11. Although we can not absolutely exclude the
existence of transcripts lacking either complete exon
10 or the ¢rst 56 bp of exon 10 in healthy controls
there is an increase in expression of both splicing
variants in those patients harbouring a splice accep-
tor mutation in the preceding intron demonstrated
by RT-PCR (Fig. 2B). In contrast to IVS933CCG
(patient T58) the GCA transition at position 315 in
intron 9 (patients T10 and T64) does neither change
the consensus sequence of the splice acceptor site nor
the predicted branch point. The secondary structure
analysis, however, positions the mutation site
IVS9315GCA into a structure motive between
branch point and splice acceptor site representing a
polypyrimidine tract (Fig. 2C). Supposing that the
branch point^splice site combination is no longer
functional under this condition the entire exon 10
will be spliced out. Alternatively, splicing of 56 bp
of exon 10 is also possible using the cryptic branch
point and splice acceptor site obviously existing in
exon 10 as identi¢ed by structure analysis. The ap-
pearance of this transition in two individual patients
(T10 and T64) both showing the identical abnormal
splicing pattern and both representing a new muta-
tion by demonstration of the absence of this muta-
tion in the una¡ected parents also suggests a direct
dependence. Additionally, the mutation IVS9315G-
CA destroys an NciI site. To lessen the possibility
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that this sequence change represents a polymorphism
it was excluded in intron 9 ampli¢ed from genomic
DNA of 50 una¡ected controls by restriction analy-
sis. RNA based mutation studies in the dystrophin
gene [26] and in the ATM gene [38] con¢rm our
observation that a distinct splice acceptor mutation
may lead to unforeseen splicing consequences includ-
ing several aberrant transcripts with skipped exons
and cryptic splice acceptors. To substantiate the pre-
dicted derivation of the aberrant transcripts from the
allele harbouring the intronic mutation we tested all
three patients (T10, T58, and T64) for 22 exonic
polymorphisms located between exons 9 and 20.
Only patient T10 was heterozygous for one of the
known polymorphisms: Ser526Ser (1596CCT) in
exon 14 which creates a TaaI recognition site. Re-
striction enzyme analysis of cloned RT-PCR prod-
ucts showed homozygosity in all wild-type transcripts
harbouring only the 1596T allele whereas aberrant
transcripts lacking exon 10 as well as those lacking
the ¢rst 56 bp of exon 10 contained exclusively the
1596C allele. Demonstration that the chromosome
bearing the IVS9315GCA mutation also carries
the 1596C haplotype corroborates production of
the aberrant transcripts from the allele with the in-
tronic mutation. Residual normal splicing from the
mutated allele in patient T10 which would be ex-
pected from the di¡erent ratios of aberrant tran-
scripts compared to patient T58 (Fig. 2B) and the
di¡erent secondary structure alterations (Fig. 2C)
could not be proven.
The retention of TSC2 intron 38 with simultane-
ous usage of a cryptic splice acceptor in exon 39 in
patient 3493 also turns out to be an exceptional event
described in TSC2 for the ¢rst time. Previously re-
ported mutations in intron 38 are the deletion of a 34
bp tandem duplication which leads to the retention
of the remaining part of intron 38 [19,39,40], and
another splice acceptor mutation (IVS3832ACG)
with unchecked consequence [41]. The susceptibility
of this region to splicing aberrations supports the
functional importance of this part of tuberin har-
bouring the rabaptin-5 binding domain [7]. The
cause of aberrant splicing in our patient 3493 is
thought to be the IVS38318ACG mutation induced
change in sequence and structure of the region be-
tween branch point and splice acceptor site (Fig. 3C).
In contrast to the situation described for intron 9 this
structure change is followed by retention of intron 38
instead of skipping exon 39, a phenomenon well dis-
cussed in [17]. Disease causing mutations in similar
regions a¡ecting the lariat formation in branch point
sequences are rarely described [42,43]. The most fre-
quently observed consequence of this mutation type
is a reduced usage of the following exon accompa-
nied by a rather mild clinical phenotype. However, in
case of patient 3493 we observed no residual normal
splicing from the mutated allele as measured by the
presence of heterozygous EcoRV polymorphism gen-
erated through a TCC transition at position 5220 in
exon 40 [44]. We con¢rmed the IVS38318ACG mu-
tation in the DNA fragments resistant towards re-
striction with EcoRV representing the 5220C allele.
Equally, all mutant RT-PCR clones and directly am-
pli¢ed RT-PCR fragments with the insertion or the
deletion corresponded to the 5220C allele. Directly
ampli¢ed wild-type transcripts and a total of ten RT-
PCR clones with inserts of normal length exclusively
contained the 5220T allele measured by complete di-
gestion with EcoRV. Moreover, the possibility of
IVS38318ACG representing a rare polymorphism
was tested by DNA restriction analysis with CfrI.
Screening of genomic DNA from 50 healthy controls
did not reveal a new CfrI site which is created by the
mutation in patient 3493.
Finally, our patient T31 represents the ¢rst case of
the insertion of an additional TSC2 exon into mature
RNA due to the mutation induced activation of an
intron 8 internal splice donor of a completely pre-
formed exon structure (Fig. 1C). The mutation
IVS8+281CCU seems to reactivate this exon by re-
pairing the sequence and structure. Based on this
assumption the question concerning the original
role of such ‘mal-exons’ arises. Translation of aber-
rant transcripts bearing this exon, designated 8a,
leads to the introduction of 38 novel amino acids
into the protein which is truncated shortly thereafter
(Fig. 1B). Inclusion of newly recognised exons due to
the creation of additional splice sites in the central
part of an intron is considered to be a rare event, for
example reported for the neuro¢bromatosis type 1
(NF1) [45] and the dystrophin gene [25]. One reason
for the under-representation of such splicing phe-
nomena is the fact that most frequently applied
DNA based mutation screening techniques com-
pletely miss these mutations. Moreover this nucleo-
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tide change creates a HphI site which was used for
restriction analysis of genomic DNA of both unaf-
fected parents as well as of 50 healthy controls. Dem-
onstration of this HphI site only in patient T31 con-
¢rmed IVS8+281CCT to represent a newly created
splice donor site. Unfortunately, the patient carried
none of the known polymorphisms between exons 1
and 11 to ¢nally proof descent of the mutated tran-
scripts.
Secondary structure modelling can be considered
as a ¢rst step towards the understanding of RNA
function and is gaining signi¢cance in alternative
and mutation induced splicing [46]. Most splicing
abnormalities, including the above mentioned, result
in premature translational termination by arising
stop codons. The mutations causing splicing mistakes
are often located in existing functional structures
thereby activating or deactivating them. These com-
mon phenomena promote the idea that the corre-
sponding reverse processes are natural ones intended
to avoid the expression of premature stop codons.
Stop mutations are able to in£uence mRNA me-
tabolism which mostly results in a reduced quantity
as a result of nonsense mediated mRNA decay [47].
Expression studies on the protein level may clarify
whether chain-terminating mutations in TSC2 merely
result in typical loss-of-function alleles or RNA sur-
veillance leads to translated truncated proteins with
changed functions dependent on the mutation type
and position. Studies on the neuro¢bromatosis type
1 (NF1) gene have shown that aberrations in mRNA
processing a¡ect protein expression and can in£uence
the clinical variability [48]. Parry et al. [49] showed
signi¢cant di¡erences in the clinical course of neuro-
¢bromatosis type 2 (NF2) patients depending on
whether the causative mutation was nonsense/frame-
shift or splice site and found a milder clinical in-
volvement in the latter. Kluwe [50] described di¡er-
ent splice site mutations in NF2 and observed
phenotypic variability among patients with respect
to mutation type and location and postulated a de-
pendence from the complexity of the splicing pattern.
The signi¢cance of variations in mRNA metabo-
lism associated with complex splicing abnormalities
in TSC2 for determining a particular clinical pheno-
type remains to be evaluated. Since four of the ¢ve
patients described in this study were younger than
2 years judgement of the in£uence of speci¢c splicing
anomalies on the clinical picture would be prema-
ture.
The present study stresses the necessity of the de-
tection of intronic variations as disease causing mu-
tations that e¡ect RNA splicing. Elucidation of the
frequency of complex splicing aberrations in TSC, so
far especially observed in the TSC2 gene, and their
consequences for protein function might help to as-
sign their signi¢cance for the clinical phenotype.
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